524 Concurrent Paclitaxel/Cisplatin (PC) with thoracic radiation (TR) in patients with stage IIIab non-small cell lung cancer (NSCLC)

Wagner, Heidi; Antonia, Scott; Williams, Colt; Alberts, M.; Hubbell, David S.; Robinson, Lary; Hilstro, J.; Ruckdeschel, John C.; Shaw, Gail L.

doi:10.1016/s0169-5002(97)89904-7

Lung Cancer

1997

DOI: 10.1016/s0169-5002(97)89904-7

|View full text |Cite

524 Concurrent Paclitaxel/Cisplatin (PC) with thoracic radiation (TR) in patients with stage IIIab non-small cell lung cancer (NSCLC)

Heidi Wagner¹,

Scott Antonia²,

Colt Williams³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1999

2001

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Locally advanced non-small cell lung cancer

Cohen

Vokes

2001

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Locally advanced non-small cell lung cancer remains a paradoxical entity to manage. Although this type of cancer is confined to the thorax and is ostensibly curable, most patients presenting at this stage of disease eventually succumb to it. The accepted therapy presently includes chemotherapy and radiation. The exact agents, schedules, and combinations need to be defined further, although cisplatin has become the widely viewed standard cytotoxic drug in this setting. Notwithstanding, newer chemotherapeutic and biologic agents are being extensively tested to find less toxic options with greater efficacy. Drugs that are gaining widespread approval include carboplatin, paclitaxel, gemcitabine, and vinorelbine. At the same time, advances in radiation therapy are triggering a revolution in dose intensity and scheduling that will one day offer superlative local control.

show abstract

Locally advanced non-small cell lung cancer

Cohen

Vokes

2001

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

show abstract

Non-small cell lung cancer: report on the 5th central European lung cancer conference

Zatloukal

1999

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

524 Concurrent Paclitaxel/Cisplatin (PC) with thoracic radiation (TR) in patients with stage IIIab non-small cell lung cancer (NSCLC)

Cited by 2 publications

References 0 publications

Locally advanced non-small cell lung cancer

Locally advanced non-small cell lung cancer

Non-small cell lung cancer: report on the 5th central European lung cancer conference

Contact Info

Product

Resources

About